Aastrom Biosciences' CEO to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference
April 29 2005 - 4:00PM
PR Newswire (US)
Aastrom Biosciences' CEO to Present at Rodman & Renshaw
Techvest 2nd Annual Global Healthcare Conference ANN ARBOR, Mich.,
April 29 /PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc.
(NASDAQ:ASTM) today announced that R. Douglas Armstrong, Ph.D.,
Chief Executive Officer and Chairman, will present at the Rodman
& Renshaw Techvest 2nd Annual Global Healthcare Conference. The
conference will be held May 4- 5th, at the InterContinental Hotel
in Paris, France. Dr. Armstrong will present in the Salon Imperial
at 7:00 a.m. (Eastern Time), or 1:00 p.m. (Paris), on Wednesday,
May 4th. Rodman & Renshaw, LLC is a privately-held,
full-service investment bank committed to fostering the long-term
success of emerging growth companies through capital raising,
strategic advice, insightful research, and the development of
institutional support. Rodman employs dedicated, experienced, and
talented professionals within its equity research, corporate
finance, and sales & trading divisions. A live webcast of
Aastrom's presentation can be accessed by logging onto the web at
http://www.wsw.com/webcast/rrshq5/astm/. An archived replay of the
presentation will also be available for 90 days after the
conference, at the same site. For more information about the Rodman
& Renshaw Techvest 2nd Annual Global Healthcare Conference,
please visit Rodman & Renshaw's website at
http://www.rodmanandrenshaw.com/. About Aastrom Biosciences, Inc.
Aastrom Biosciences, Inc. (NASDAQ:ASTM) is developing
patient-specific products for the repair or regeneration of human
tissues, utilizing the Company's proprietary adult stem cell
technology. Aastrom's strategic position in the tissue regeneration
sector is enabled by its proprietary Tissue Repair Cells (TRCs), a
mix of bone marrow-derived adult stem and progenitor cells, and the
AastromReplicell(R) System, an industry-unique automated cell
production platform used to produce cells for clinical use. TRCs
are the core component of the products Aastrom is developing for
severe bone fractures, ischemic vascular disease, jaw
reconstruction and spine fusion, with Phase I/II level clinical
trials active in the U.S. and EU for some of these indications. For
more information, visit Aastrom's website at
http://www.aastrom.com/. This document contains forward-looking
statements, including without limitation, statements regarding
product development objectives, market development plans, and
potential advantages and applications of the AastromReplicell(R)
System and related products, which involve certain risks and
uncertainties. The forward-looking statements are also identified
through use of the words "plans," and other words of similar
meaning. Actual results may differ significantly from the
expectations contained in the forward- looking statements. Among
the factors that may result in differences are the results obtained
from clinical trial activities, regulatory approval requirements,
and the availability of resources. These and other significant
factors are discussed in greater detail in Aastrom's Annual Report
on Form 10- K and other filings with the Securities and Exchange
Commission. CONTACTS: Kris M. Maly or Kevin McGrath Becky Anderson
Cameron Associates Investor Relations Department Phone: (212)
245-4577 Aastrom Biosciences, Inc. Phone: (734) 930-5777
DATASOURCE: Aastrom Biosciences, Inc. CONTACT: Kris M. Maly or
Becky Anderson, Investor Relations Department, +1-734-930-5777,
both of Aastrom Biosciences, Inc.; or Kevin McGrath of Cameron
Associates, +1-212-245-4577 Web site: http://www.aastrom.com/
http://www.wsw.com/webcast/rrshq5/astm
http://www.rodmanandrenshaw.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024